For citations:
Karateev DE, Mazurov VI, Zonova EV, Nesmeyanova OB, Plaksina TV, Krechikova DG, Reshetko OV, Denisov LN, Gordeev IG, Pokrovskaya TG, Antipova OV, Kropotina TV, Povarova TV, Shesternya PA, Ushakova EN, Soroka NF, Pristrom AM, Eremeeva AV, Chernyaeva EV, Ivanov RA, Usacheva UV. Comparative efficacy and safety of infliximab biosimilar (BCD-055) and innovator infliximab in patients with ankylosing spondylitis (results of international, multiple-center, double-blind phase I and phase III clinical studies). Sovremennaya Revmatologiya=Modern Rheumatology Journal. 2017;11(3):14-25. (In Russ.) https://doi.org/10.14412/1996-7012-2017-3-14-25
Email this article 